TY - JOUR
T1 - Primary lymphoma of bone - A retrospective study. Experience at the Northern Israel Oncology Center (1979-2000)
AU - Stein, M. E.
AU - Kuten, A.
AU - Gez, E.
AU - Rosenblatt, K. E.
AU - Drumea, K.
AU - Ben-Shachar, M.
AU - Zidan, J.
AU - Haim, N.
AU - Epelbaum, R.
PY - 2003
Y1 - 2003
N2 - Objective: This retrospective study describes our experience with the diagnosis, treatment, results and long-term follow-up of primary bone lymphoma (PBL). Patients and Methods: Nineteen patients diagnosed with PBL were reviewed. Seven patients presented with stage IE disease, four with stage IIE (regional lymphadenopathy), and eight with stage IV disease (disseminated bone involvement). Only one stage IV patient exhibited 'B' symptoms. The majority (72%) demonstrated diffuse, large cell, B-type lymphoma. All patients were treated with adriamycin-based chemotherapy and consolidation radiotherapy to the primary site (8 patients: early PBL) or the most bulky area (3 patients: stage IV PBL). Results: Ten stage IE/IIE patients are alive with no evidence of disease (NED) and only one died due to metastatic secondary lung cancer while with NED from his PBL. Eight stage IV patients are alive with NED. Median follow-up for all living patients: 77 months. Side effects were mild and did not necessitate delay in treatment. Conclusions: Our departmental policy of treating PBL patients with an anthracycline-based regimen and involved field radiotherapy proved to be successful in achieving excellent long-term, disease-free survival. Phase III randomized, controlled, clinical trials will determine the true role of consolidation radiotherapy in PBL, when considering severe late side effects, including radiation-induced bone tumors.
AB - Objective: This retrospective study describes our experience with the diagnosis, treatment, results and long-term follow-up of primary bone lymphoma (PBL). Patients and Methods: Nineteen patients diagnosed with PBL were reviewed. Seven patients presented with stage IE disease, four with stage IIE (regional lymphadenopathy), and eight with stage IV disease (disseminated bone involvement). Only one stage IV patient exhibited 'B' symptoms. The majority (72%) demonstrated diffuse, large cell, B-type lymphoma. All patients were treated with adriamycin-based chemotherapy and consolidation radiotherapy to the primary site (8 patients: early PBL) or the most bulky area (3 patients: stage IV PBL). Results: Ten stage IE/IIE patients are alive with no evidence of disease (NED) and only one died due to metastatic secondary lung cancer while with NED from his PBL. Eight stage IV patients are alive with NED. Median follow-up for all living patients: 77 months. Side effects were mild and did not necessitate delay in treatment. Conclusions: Our departmental policy of treating PBL patients with an anthracycline-based regimen and involved field radiotherapy proved to be successful in achieving excellent long-term, disease-free survival. Phase III randomized, controlled, clinical trials will determine the true role of consolidation radiotherapy in PBL, when considering severe late side effects, including radiation-induced bone tumors.
KW - Chemo-radiotherapy regimes
KW - Primary bone lymphoma
KW - Prolonged survival
UR - http://www.scopus.com/inward/record.url?scp=0038651255&partnerID=8YFLogxK
U2 - 10.1159/000070288
DO - 10.1159/000070288
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 12759527
AN - SCOPUS:0038651255
SN - 0030-2414
VL - 64
SP - 322
EP - 327
JO - Oncology
JF - Oncology
IS - 4
ER -